All Stories

  1. Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment

    Article • European Journal Of Haematology, September 2018, Wiley

    Dr Lev Shvidel

  2. Outcomes of second-line treatment after fludarabine cyclophosphamide and rituximab in patients with chronic lymphocytic leukemia outside clinical trials

    Article • European Journal Of Haematology, August 2018, Wiley

    Dr Lev Shvidel, Dr Tamar Tadmor

  3. Persistently low lymphocyte counts after FCR therapy for chronic lymphocytic leukemia are associated with longer overall survival

    Article • Hematological Oncology, June 2017, Wiley

    Dr Lev Shvidel, Dr Tamar Tadmor

  4. Relationship between comorbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study

    Article • British Journal of Haematology, June 2017, Wiley

    Dr Lev Shvidel

  5. A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia:A patient based approach

    Article • British Journal of Haematology, May 2017, Wiley

    Dr Lev Shvidel

  6. Serum immunoglobulin levels at diagnosis have no prognostic significance in stage A chronic lymphocytic leukemia: a study of 1113 cases from the Israeli CLL Study Group

    Article • European Journal Of Haematology, March 2014, Wiley

    Dr Lev Shvidel